CHEK1 and cancer: Lung cancer cells that acquire Adavosertib resistance have also been reported to have upregulated ATR and Chk1 activity, which suggests that these kinases also play an important role in determining cancer cell sensitivity to Adavosertib (Sen et al., 2017).